Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network.
We present the results of a nationwide survey of infectious disease consultants to identify mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor compounds and other novel targeted therapies. Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context.
Winthrop
Kevin L
KL
Oregon Health & Sciences University, Portland 97239, USA. Winthrop@ohsu.edu
Yamashita
S
S
Beekmann
S E
SE
Polgreen
P M
PM
D001691:Biological Therapy / Q000009:adverse effects*; D003625:Data Collection; D006801:Humans; D007255:Information Services; D009164:Mycobacterium Infections / Q000209:etiology*; D009894:Opportunistic Infections / Q000139:chemically induced* / Q000209:etiology / Q000517:prevention & control; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects*
D014409:Tumor Necrosis Factor-alpha